

David Durantel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6810232/publications.pdf>

Version: 2024-02-01

118
papers

7,669
citations

57758

44
h-index

54911

84
g-index

126
all docs

126
docs citations

126
times ranked

8308
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 447-464.	46.4	925
2	Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA. <i>Science</i> , 2014, 343, 1221-1228.	12.6	774
3	Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. <i>Journal of Hepatology</i> , 2011, 55, 996-1003.	3.7	361
4	COVID-19: Discovery, diagnostics and drug development. <i>Journal of Hepatology</i> , 2021, 74, 168-184.	3.7	302
5	Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. <i>Journal of Hepatology</i> , 2003, 39, 1085-1089.	3.7	288
6	Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. <i>Hepatology</i> , 2005, 41, 1391-1398.	7.3	260
7	Towards an HBV cure: state-of-the-art and unresolved questions – report of the ANRS workshop on HBV cure. <i>Gut</i> , 2015, 64, 1314-1326.	12.1	234
8	New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. <i>Journal of Hepatology</i> , 2016, 64, S117-S131.	3.7	172
9	Study of the Mechanism of Antiviral Action of Iminosugar Derivatives against Bovine Viral Diarrhea Virus. <i>Journal of Virology</i> , 2001, 75, 8987-8998.	3.4	149
10	A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses. <i>Hepatology</i> , 2016, 63, 35-48.	7.3	131
11	Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. <i>Journal of General Virology</i> , 2009, 90, 127-135.	2.9	128
12	Antiviral Therapies and Prospects for a Cure of Chronic Hepatitis B. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021501-a021501.	6.2	128
13	Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, 897-909.	3.7	125
14	Control of hepatitis B virus replication by innate response of HepaRG cells. <i>Hepatology</i> , 2010, 51, 63-72.	7.3	124
15	Early inhibition of hepatocyte innate responses by hepatitis B virus. <i>Journal of Hepatology</i> , 2015, 63, 1314-1322.	3.7	114
16	RNA helicase DEAD box protein 5 regulates Polycomb repressive complex 2/Hox transcript antisense intergenic RNA function in hepatitis B virus infection and hepatocarcinogenesis. <i>Hepatology</i> , 2016, 64, 1033-1048.	7.3	108
17	Receptor Complementation and Mutagenesis Reveal SR-BI as an Essential HCV Entry Factor and Functionally Imply Its Intra- and Extra-Cellular Domains. <i>PLoS Pathogens</i> , 2009, 5, e1000310.	4.7	107
18	Statins potentiate the <i>in vitro</i> anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. <i>Hepatology</i> , 2009, 50, 6-16.	7.3	104

#	ARTICLE	IF	CITATIONS
19	Hepatitis B Virus Requires Intact Caveolin-1 Function for Productive Infection in HepaRG Cells. <i>Journal of Virology</i> , 2010, 84, 243-253.	3.4	101
20	The HepaRG Cell Line: Biological Properties and Relevance as a Tool for Cell Biology, Drug Metabolism, and Virology Studies. <i>Methods in Molecular Biology</i> , 2010, 640, 261-272.	0.9	97
21	A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. <i>Hepatology</i> , 2004, 40, 855-864.	7.3	97
22	Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism. <i>Journal of Hepatology</i> , 2018, 68, 922-931.	3.7	88
23	The diverse functions of the hepatitis B core/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals. <i>Antiviral Research</i> , 2018, 149, 211-220.	4.1	86
24	Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	83
25	Antiviral Effect of N-Butyldeoxynojirimycin against Bovine Viral Diarrhea Virus Correlates with Misfolding of E2 Envelope Proteins and Impairment of Their Association into E1-E2 Heterodimers. <i>Journal of Virology</i> , 2001, 75, 3527-3536.	3.4	79
26	HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes. <i>Antiviral Research</i> , 2016, 136, 19-31.	4.1	73
27	Treatment of hepatitis B virus-infected cells with α -glucosidase inhibitors results in production of virions with altered molecular composition and infectivity. <i>Antiviral Research</i> , 2007, 76, 30-37.	4.1	66
28	Hepatitis B Virus Evasion From Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase Sensing in Human Hepatocytes. <i>Hepatology</i> , 2018, 68, 1695-1709.	7.3	66
29	Synthesis of 1,2,3-triazolo-carbanucleoside analogues of ribavirin targeting an HCV in replicon. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 3633-3639.	3.0	65
30	Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection. <i>Journal of Hepatology</i> , 2019, 71, 1086-1098.	3.7	62
31	Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus. <i>Antiviral Research</i> , 2016, 130, 36-45.	4.1	61
32	Polo-like kinase 1 is a proviral host factor for hepatitis B virus replication. <i>Hepatology</i> , 2017, 66, 1750-1765.	7.3	60
33	Expression and functionality of Toll- and RIG-like receptors in HepaRG cells. <i>Journal of Hepatology</i> , 2015, 63, 1077-1085.	3.7	59
34	Effects of Interferon, Ribavirin, and Iminosugar Derivatives on Cells Persistently Infected with Noncytopathic Bovine Viral Diarrhea Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 497-504.	3.2	58
35	Novel targets for hepatitis B virus therapy. <i>Liver International</i> , 2017, 37, 33-39.	3.9	58
36	Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes. <i>Scientific Reports</i> , 2018, 8, 5390.	3.3	57

#	ARTICLE	IF	CITATIONS
37	Immune-modulators to combat hepatitis B virus infection: From IFN- α to novel investigational immunotherapeutic strategies. <i>Antiviral Research</i> , 2015, 122, 69-81.	4.1	56
38	Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. <i>Current Opinion in Investigational Drugs</i> , 2009, 10, 860-70.	2.3	56
39	DNA Methylation of Hepatitis B Virus (HBV) Genome Associated with the Development of Hepatocellular Carcinoma and Occult HBV Infection. <i>Journal of Infectious Diseases</i> , 2010, 202, 700-704.	4.0	55
40	Characterization of the Inflammasome in Human Kupffer Cells in Response to Synthetic Agonists and Pathogens. <i>Journal of Immunology</i> , 2016, 197, 356-367.	0.8	53
41	Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors. <i>Journal of General Virology</i> , 2007, 88, 1133-1143.	2.9	51
42	Innate Antiviral Immune Responses to Hepatitis B Virus. <i>Viruses</i> , 2010, 2, 1394-1410.	3.3	51
43	Interplay between the Hepatitis B Virus and Innate Immunity: From an Understanding to the Development of Therapeutic Concepts. <i>Viruses</i> , 2017, 9, 95.	3.3	50
44	Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector. <i>Antiviral Research</i> , 2017, 145, 14-19.	4.1	49
45	Hepatitis delta virus: From biological and medical aspects to current and investigational therapeutic options. <i>Antiviral Research</i> , 2015, 122, 112-129.	4.1	44
46	Antiviral effect of α -glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles. <i>Journal of General Virology</i> , 2006, 87, 861-871.	2.9	43
47	Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector. <i>Journal of General Virology</i> , 2008, 89, 1819-1828.	2.9	41
48	NOD1 Participates in the Innate Immune Response Triggered by Hepatitis C Virus Polymerase. <i>Journal of Virology</i> , 2016, 90, 6022-6035.	3.4	39
49	Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. <i>Journal of Clinical Virology</i> , 2005, 34, S34-S43.	3.1	38
50	Suboptimal Response to Adefovir Dipivoxil Therapy for Chronic Hepatitis B in Nucleoside-Naive Patients is not due to Pre-Existing Drug-Resistant Mutants. <i>Antiviral Therapy</i> , 2008, 13, 381-388.	1.0	38
51	Characterization of Pattern Recognition Receptor Expression and Functionality in Liver Primary Cells and Derived Cell Lines. <i>Journal of Innate Immunity</i> , 2018, 10, 339-348.	3.8	36
52	Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic Cells. <i>PLoS ONE</i> , 2016, 11, e0156063.	2.5	35
53	Management and prevention of drug resistance in chronic hepatitis B. <i>Liver International</i> , 2009, 29, 108-115.	3.9	34
54	Very-Low-Density Lipoprotein (VLDL)-Producing and Hepatitis C Virus-Replicating HepG2 Cells Secrete No More Lipovirions than VLDL-Deficient Huh7.5 Cells. <i>Journal of Virology</i> , 2013, 87, 5065-5080.	3.4	34

#	ARTICLE	IF	CITATIONS
55	Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy. <i>Journal of Medical Virology</i> , 2004, 74, 41-53.	5.0	33
56	Innate response to hepatitis B virus infection: Observations challenging the concept of a stealth virus. <i>Hepatology</i> , 2009, 50, 1692-1695.	7.3	33
57	Glucosidase inhibitors as antiviral agents for hepatitis B and C. <i>Current Opinion in Investigational Drugs</i> , 2007, 8, 125-9.	2.3	32
58	In Vitro Characterization of the Anti-Hepatitis B Virus Activity and Cross-Resistance Profile of 2â€²,3â€²-Dideoxy-3â€²-Fluoroguanosine. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 955-961.	3.2	31
59	Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis. <i>Journal of Hepatology</i> , 2019, 71, 763-772.	3.7	31
60	Restoration of RNA helicase DDX5 suppresses hepatitis B virus (HBV) biosynthesis and Wnt signaling in HBV-related hepatocellular carcinoma. <i>Theranostics</i> , 2020, 10, 10957-10972.	10.0	31
61	Liver macrophages: Friend or foe during hepatitis B infection?. <i>Liver International</i> , 2018, 38, 1718-1729.	3.9	29
62	Hepatitis C Virus Fails To Activate NF- κ B Signaling in Plasmacytoid Dendritic Cells. <i>Journal of Virology</i> , 2012, 86, 1090-1096.	3.4	28
63	Hepatitis B virus Core protein nuclear interactome identifies SRSF10 as a host RNA-binding protein restricting HBV RNA production. <i>PLoS Pathogens</i> , 2020, 16, e1008593.	4.7	28
64	A new strategy for studying In Vitro the drug susceptibility of clinical isolates of human hepatitis B virus. <i>Hepatology</i> , 2004, 40, 855-864.	7.3	27
65	Temporal Expression of the AcMNPVlef-4Gene and Subcellular Localization of the Protein. <i>Virology</i> , 1998, 241, 276-284.	2.4	25
66	Lymphotoxin Signaling Is Initiated by the Viral Polymerase in HCV-linked Tumorigenesis. <i>PLoS Pathogens</i> , 2013, 9, e1003234.	4.7	24
67	An immortalized human liver endothelial sinusoidal cell line for the study of the pathobiology of the liver endothelium. <i>Biochemical and Biophysical Research Communications</i> , 2014, 450, 7-12.	2.1	24
68	Aberrant DNA methylation of imprinted loci in hepatocellular carcinoma and after in vitro exposure to common risk factors. <i>Clinical Epigenetics</i> , 2015, 7, 15.	4.1	24
69	RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes. <i>Gut</i> , 2022, 71, 991-1005.	12.1	23
70	Characterization of the double-stranded RNA responses in human liver progenitor cells. <i>Biochemical and Biophysical Research Communications</i> , 2008, 368, 556-562.	2.1	22
71	Targeting Innate Immunity: A New Step in the Development of Combination Therapy for Chronic Hepatitis B. <i>Gastroenterology</i> , 2013, 144, 1342-1344.	1.3	22
72	Circulating and Hepatic BDCA1+, BDCA2+, and BDCA3+ Dendritic Cells Are Differentially Subverted in Patients With Chronic HBV Infection. <i>Frontiers in Immunology</i> , 2019, 10, 112.	4.8	22

#	ARTICLE	IF	CITATIONS
73	Long Alkylchain Iminosugars Block the HCV p7 Ion Channel. <i>Advances in Experimental Medicine and Biology</i> , 2005, 564, 3-4.	1.6	21
74	Interplay between hepatitis B virus and TLR2-mediated innate immune responses: Can restoration of TLR2 functions be a new therapeutic option?. <i>Journal of Hepatology</i> , 2012, 57, 486-489.	3.7	21
75	Hepatitis B virus replication in primary macaque hepatocytes: Crossing the species barrier toward a new small primate model. <i>Hepatology</i> , 2010, 51, 1954-1960.	7.3	20
76	HBV infection and HCC: the "dangerous liaisons"™. <i>Gut</i> , 2018, 67, 787-788.	12.1	20
77	Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006377.	3.0	20
78	Hepatitis B virus infection enhances susceptibility toward adeno-associated viral vector transduction <i>in vitro</i> and <i>in vivo</i> . <i>Hepatology</i> , 2014, 59, 2110-2120.	7.3	19
79	Role of disulfide bond formation in the folding and assembly of the envelope glycoproteins of a pestivirus. <i>Biochemical and Biophysical Research Communications</i> , 2002, 296, 470-476.	2.1	18
80	Short peptide nucleic acids (PNA) inhibit hepatitis C virus internal ribosome entry site (IRES) dependent translation <i>in vitro</i> . <i>Antiviral Research</i> , 2008, 80, 280-287.	4.1	18
81	Epidermal Growth Factor Receptor-Dependent Mutual Amplification between Netrin-1 and the Hepatitis C Virus. <i>PLoS Biology</i> , 2016, 14, e1002421.	5.6	18
82	Hepatitis B Virus Blocks the CRE/CREB Complex and Prevents TLR9 Transcription and Function in Human B Cells. <i>Journal of Immunology</i> , 2018, 201, 2331-2344.	0.8	18
83	A dual role for hepatocyte-intrinsic canonical NF- κ B signaling in virus control. <i>Journal of Hepatology</i> , 2020, 72, 960-975.	3.7	18
84	Going towards more relevant cell culture models to study the <i>in vitro</i> replication of serum-derived hepatitis C virus and virus/host cell interactions?. <i>Journal of Hepatology</i> , 2007, 46, 1-5.	3.7	17
85	Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1287-1294.	3.0	17
86	Hypoxia-inducible Factor 1 Alpha-mediated RelB/APOBEC3B Down-regulation Allows Hepatitis B Virus Persistence. <i>Hepatology</i> , 2021, 74, 1766-1781.	7.3	17
87	Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication <i>in vitro</i> . <i>Antiviral Therapy</i> , 2009, 14, 131-135.	1.0	17
88	Ribavirin restores IFN- α responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. <i>Gut</i> , 2016, 65, 672-682.	12.1	16
89	New treatments to reach functional cure: Virological approaches. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 329-336.	2.4	16
90	Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied?. <i>Antiviral Therapy</i> , 2010, 15, 521-527.	1.0	15

#	ARTICLE	IF	CITATIONS
91	Mechanism of action of ribavirin in anti-HCV regimens: new insights for an age-old question?. <i>Gut</i> , 2014, 63, 3-4.	12.1	15
92	Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	15
93	Hypoxic gene expression in chronic hepatitis B virus infected patients is not observed in state-of-the-art in vitro and mouse infection models. <i>Scientific Reports</i> , 2020, 10, 14101.	3.3	12
94	Control of APOBEC3B induction and cccDNA decay by NF- κ B and miR-138-5p. <i>JHEP Reports</i> , 2021, 3, 100354.	4.9	11
95	Loss of hepatitis D virus infectivity upon farnesyl transferase inhibitor treatment associates with increasing RNA editing rates revealed by a new RT-ddPCR method. <i>Antiviral Research</i> , 2022, 198, 105250.	4.1	11
96	Management of Merkel cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 441-445.	2.4	10
97	Synthesis of 5-haloethynyl- and 5-(1,2-dihalo)vinyluracil nucleosides: Antiviral activity and cellular toxicity. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 6015-6024.	3.0	10
98	Evidence for long-term association of virion-delivered HBV core protein with cccDNA independently of viral protein production. <i>JHEP Reports</i> , 2021, 3, 100330.	4.9	10
99	Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. <i>Antiviral Therapy</i> , 2008, 13, 381-8.	1.0	10
100	Interplay Between CMGC Kinases Targeting SR Proteins and Viral Replication: Splicing and Beyond. <i>Frontiers in Microbiology</i> , 2021, 12, 658721.	3.5	9
101	Genomic responses to hepatitis B virus (HBV) infection in primary human hepatocytes. <i>Oncotarget</i> , 2015, 6, 44877-44891.	1.8	9
102	Novel Alpha Interferon (IFN- λ) Variant with Improved Inhibitory Activity against Hepatitis C Virus Genotype 1 Replication Compared to IFN- λ 2b Therapy in a Subgenomic Replicon System. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3984-3991.	3.2	8
103	Current and emerging therapeutic approaches to hepatitis C infection. <i>Expert Review of Anti-Infective Therapy</i> , 2003, 1, 441-454.	4.4	7
104	Fast Differentiation of HepaRG Cells Allowing Hepatitis B and Delta Virus Infections. <i>Cells</i> , 2020, 9, 2288.	4.1	7
105	Antiviral Activity of PLK1-Targeting siRNA Delivered by Lipid Nanoparticles in HBV-Infected Hepatocytes. <i>Antiviral Therapy</i> , 2020, 25, 151-162.	1.0	7
106	Two-dimensional-cultures of primary human hepatocytes allow efficient HBV infection: Old tricks still work!. <i>Journal of Hepatology</i> , 2020, 73, 449-451.	3.7	6
107	Nucleic Acid Polymers are Effective in Targeting Hepatitis B Surface Antigen, but More Trials Are Needed. <i>Gastroenterology</i> , 2020, 158, 2051-2054.	1.3	6
108	Inhibitory Effect of IL-1 β on HBV and HDV Replication and HBs Antigen-Dependent Modulation of Its Secretion by Macrophages. <i>Viruses</i> , 2022, 14, 65.	3.3	6

#	ARTICLE	IF	CITATIONS
109	Hepatitis B virus exploits C-type lectin receptors to hijack cDC1s, cDC2s and pDCs. <i>Clinical and Translational Immunology</i> , 2020, 9, e1208.	3.8	3
110	Is there any need for new, long-acting nucleos(t)ide analogues for the treatment of hepatitis B infection?. <i>Journal of Hepatology</i> , 2021, 74, 1011-1014.	3.7	3
111	Inducers of the NF- κ B pathways impair hepatitis delta virus replication and strongly decrease progeny infectivity in vitro. <i>JHEP Reports</i> , 2022, 4, 100415.	4.9	3
112	Virus morphogenesis and viral entry as alternative targets for novel hepatitis C antivirals. <i>Future Virology</i> , 2006, 1, 197-209.	1.8	2
113	Who Defends the Stem Cell's Citadel?. <i>Cell Stem Cell</i> , 2018, 22, 287-289.	11.1	1
114	A first experience of transduction for differentiated HepaRG cells using lentiviral technology. <i>Scientific Reports</i> , 2019, 9, 12910.	3.3	1
115	How to get away with liver innate immunity? A viruses' tale. <i>Liver International</i> , 2021, 41, 2547-2559.	3.9	1
116	Hepatitis C virus fails to activate NF-kappaB signaling in plasmacytoid dendritic cells. <i>Retrovirology</i> , 2012, 9, .	2.0	0
117	Clinical Aspects of Hepatitis C Virus Infection. , 0, , 241-264.		0
118	New In Vitro Testing Systems for Hepatitis B and C Viruses. , 0, , 824-840.		0